Physician profile
Amy Thomas
NPI 1205227071
$4,508.85
in general payments reported to CMS, 2019-2025
33 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,007 · 2022: $351 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $150.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $557.46 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $443.37 | 2021 | |
| Esperion Therapeutics, INC. | $372.69 | 2021-2022 | |
| Amgen INC. | $351.81 | 2021-2022 | |
| Novo Nordisk INC | $270.30 | 2021-2025 | Wegovy |
| Biohaven Pharmaceuticals, INC. | $260.14 | 2021 | |
| Glaxosmithkline, LLC. | $228.40 | 2021 | |
| Sanofi-Aventis U.S. LLC | $216.98 | 2021-2022 | |
| Lilly USA, LLC | $207.69 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.49 | 2021-2022 | |
| Pfizer INC. | $179.94 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $165.71 | 2021 | |
| Janssen Pharmaceuticals, INC | $140.12 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $136.76 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $98.66 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $95.18 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $94.43 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.24 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $53.69 | 2022 | |
| Sunovion Pharmaceuticals INC. | $51.06 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.14 | 2021-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.81 | 2021-2022 | |
| Eisai INC. | $38.38 | 2021 | |
| Alexion Pharmaceuticals, INC. | $35.11 | 2021 | |
| Astellas Pharma US INC | $26.53 | 2021 | |
| Verona Pharma, INC. | $17.57 | 2025 | Ohtuvayre |
| Avanir Pharmaceuticals, INC. | $16.90 | 2021 | |
| Supernus Pharmaceuticals, INC. | $16.57 | 2021 | |
| Mylan Specialty L.P. | $16.43 | 2021 | |
| Abbott Laboratories | $15.41 | 2021 | |
| Lundbeck LLC | $14.57 | 2025 | Rexulti |
| Biogen, INC. | $13.11 | 2021 | |
| Clarus Therapeutics INC. | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.